secwatch.observer — SEC 8-K summary
======================================

Issuer:     Pulmonx Corp (LUNG)
CIK:        0001127537
Form:       8-K
Filed at:   2026-04-29T23:59:59+00:00
Accession:  0001127537-26-000020
Event type: earnings
Sentiment:  negative
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Pulmonx Q1 revenue falls 9% YoY to $20.6M; net loss $13.7M
----------------------------------------------------------

- Worldwide revenue $20.6M (-9% YoY, -12% constant currency); U.S. $13.3M (-7%), international $7.3M (-12%).
- Ex-China international revenue grew 22% YoY; China sales paused awaiting registration renewal.
- Gross margin improved to 78% (vs 73% Q1 2025); total op. expenses $29.0M (-6% YoY).
- Adjusted EBITDA loss $8.5M; net loss $13.7M ($0.33 per share) vs $14.4M ($0.36) a year ago.
- FY 2026 outlook reaffirmed: revenue $90-92M, gross margin ~75%, opex $113-115M, cash burn ~$23M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/0001127537-26-000020-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1127537/000112753726000020/lung-20260429.htm
  HTML page:      https://secwatch.observer/filing/0001127537-26-000020

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer